본문 바로가기
KERD
논문KCI 등재

초기단계의 비소세포폐암종에서 Telomerase ReverseTranscriptase 단백발현이 예후지표인자로서 가지는 의의

The Expression of Telomerase Reverse Transcriptase Proteinis an Independent Prognostic Marker in Early Stage Non-Small Cell Lung Carcinomas

박경신|유진영|이교영|정찬권|이아원|정지한
대한병리학회|2007.04|Journal of Pathology and Translational Medicine|제41권 제2호|pp. 95-102

2

조회

0

다운로드

1

인용

0

참고문헌

주제분류병리학

초록

Abstract

Background : The catalytic subunit of telomerase, hTERT (telomerase reverse transcriptase), is one of the most important components of telomerase, and performs a pivotal role in the mechanism underlying the regulation of telomerase activity in cellular immortalization and carcinogenesis. The principal objective of this study was to investigate hTERT expression in patients with non-small cell lung carcinomas (NSCLCs), and to evaluate its clinical significance and association with the expression of p16 and p53. Methods : Using tissue microarray, the protein expression profiles of hTERT, p16 and p53 were investigated via immunohistochemistry in 167 samples of NSCLCs. Results : Expression was observed in 54.5% (91/167) of the tumors, which were predominantly squamous cell carcinomas. Patients evidencing hTERT expression in their tumors exhibited significantly poorer survival rates than did patients without hTERT expression in early-stage NSCLCs (p=0.0125). According to the results of our Cox regression analysis, hTERT expression proved to be an independent prognostic factor (p= 0.006), particularly for squamous cell carcinomas (p=0.019). hTERT expression was not correlated with p16 expression, but was rather associated with the expression of p53 (p=0.002). Conclusions : Our results show that hTERT may perform a function in the progression of NSCLC, and that its detection may be useful in predicting the prognosis of NSCLC patients in the early stages of the disease, as well as in the development of a targeted therapy in these tumors.

참고문헌 (26)

  1. "Immunohistochemical markersof prognosis in non-small cell lung cancer:a review and proposalfor a multiphase approach to marker evaluation", 59, pp.790~800 (2006)
  2. "Ministry of Health and Welfare Republicof Korea 2002 Annual Report of the Korea Central CancerRegistry" (2002)
  3. "Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers", 22, pp.4575~4583 (2004)
  4. "Reverse transcriptase motifs in the catalytic subunit of telomerase", 276, pp.561~567 (1997)
  5. "telomerase contains evolutionarily conserved catalytic and structural subunits", 11, pp.3109~3115 (1997)
  6. "Immunohistochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non tumor tissue sections", 18, pp.1561~1567 (1999)
  7. "Immunohistochemicaldetection of human telomerase reverse transcriptase in humanliver tissues", 19, pp.3888~3893 (2000)
  8. "Expression of telomerase reverse transcriptase (TERT) in malignant mesotheliomas", 26, pp.365~370 (2002)
  9. "Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: A clinicopathologic study", 98, pp.396~402 (2005)
  10. "Telomerase subunitimmunoreactivity and recurrence in colorectal cancer", 53, pp.188~191 (2006)
  11. "Both Rb", p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells, 1998, pp.396, 84~88
  12. "Introduction of p16INK4a inhibits telomerase activity through transcriptional suppresion of human telomerase reverse transcriptase expression in human gliomas", 24, pp.1213~1220 (2004)
  13. "Adenoviral expression of p53represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription", 6, pp.1239~1247 (2000)
  14. "Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells", 19, pp.5123~5133 (2000)
  15. "Diagnostic approach using the expression profiling of the P53 tumor suppressor gene and its related proteins in ovarian epithelial tumors", 15, pp.453~461 (2005)
  16. "Creation of human tumour cells with defined genetic elements", 400, pp.464~468 (1999)
  17. "Loss of telomerase activity may be apotential favorable prognostic marker in lung carcinomas", 41, pp.163~169 (2003)
  18. "Expression of human telomerasesubunit genes in primary lung cancer and its clinical significance", 70, pp.401~405 (2000)
  19. "Clinicopathologic significance of telomerase activity and hTERT mRNA expression in non-small cell lung cancer", 34, pp.219~226 (2001)
  20. "The diagnostic and prognostic relevance of human telomerase reverse transcriptase mRNA expression detected in situ in patients with non small cell lung carcinomas", 98, pp.1008~1013 (2003)
  21. "Alterations in telomeric repeatlength in lung cancer are associated with loss of heterozygosityin p53 and Rb", 10, pp.937~944 (1995)
  22. "Can ends justify the means?: telomeres and the mechanisms of replicative senescence and immortalization in mammalian cells", 95, pp.9078~9081 (1998)
  23. "Alterations of INK4a expression and telomerase activation in meningiomaprogression", 55, pp.149~158 (2001)
  24. "Wild-type p16INK4a suppresses cell growth, telomerase activity and DNA repair in human breast cancer MCF-7 cells", 24, pp.1597~1605 (2004)
  25. "Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies", 88, pp.1442~1455 (1996)
  26. "Telomerase activity during spontaneousimmortalization of Li-Fraumeni syndrome skin fibroblasts", 17, pp.709~717 (1998)

관련 논문AI추천

비소세포 폐암종에서 Survivin의 발현 - 예후 및 종양 표지자와의 상관성-정민정, 천봉권대한병리학회 · Journal of Pathology and Translational Medicine2005 · 제39권 제3호비소세포폐암종에서 Galectin-3 단백 발현의 의의강현정, 설미영, 신동훈, 이민기, 이창훈대한병리학회 · Journal of Pathology and Translational Medicine2006 · 제40권 제5호비소세포폐암종에서 p73의 발현강석진, 박경신, 유진영, 이교영, 정지한, 정찬권, 최현주대한병리학회 · Journal of Pathology and Translational Medicine2007 · 제41권 제2호비소세포 폐암종의 상피성장인자 수용체 상태와 임상-병리학적 연관성: 단백 발현, 유전자 증폭 및 생존분석최진, 이승구, 장세진대한병리학회 · Journal of Pathology and Translational Medicine2007 · 제41권 제6호비소세포 폐암종에서 Thymidylate Synthase의 발현강석진, 김성환, 김수지, 김치홍, 김훈교, 송소향, 심병용, 안명임, 유진영, 조규도, 조덕곤대한병리학회 · Journal of Pathology and Translational Medicine2005 · 제39권 제6호비소세포 폐암종에서 bcl-2, p53, VEGF의 발현: 미세혈관밀도 및 예후와의 상관관계강석진, 강창석, 유진영, 정지한, 최현주대한병리학회 · Journal of Pathology and Translational Medicine2005 · 제39권 제2호

이 간행물의 다른 논문 (11건)

신 이형성증에서 PAX2 발현정현주, 이윤희, 홍순원, 정우희pp. 69-78자궁경부의 전암 병변 및 침윤성암종에서 Mikdine의 발현 양상한지영, 박인서, 송은섭, 김준미, 김루시아, 주영채, 최석진pp. 79-86수모세포종에서 Vimentin과 Survivin의 표현율과 예후와의 관계권지은, 김태승, 석재연, 김세훈, 이윤희pp. 87-94태아수종의 원인: 149부검례 분석박성혜, 지제근, 이호창pp. 103-108비소세포폐암종에서 p73의 발현이교영, 정지한, 박경신, 최현주, 유진영, 강석진, 정찬권pp. 109-115
원문 보기